SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Alan Turing Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAlan Turing
Date of birth1912-06-23
IdentifiersMRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290
Document date2026-11-01
AuthorRupert Hallam, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent. Concerns: Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners; Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1953-04-14activeS
Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route1953-06-09activeS
Ibuprofen 400 mg oral tablet, one tablet by mouth up to three times a day with food for no more than 5 daysOne tablet up to three times a day with food, for no more than 5 daysOral route1953-08-25 to 1953-08-30completedS

Procedures

ProcedureDatesStatusEvidence
Scrotal ultrasound for gynecomastia workup: testes about 15 mL each, homogeneous, no mass; no varicocele1953-04-28 to 1953-04-28completedS
Advance care planning conversation, about 20 minutes1953-10-20 to 1953-10-20completedS

Immunizations

DateVaccineStatusEvidence
1952-10-14Influenza vaccine, 1952-1953 seasoncompletedS
1948-05-11Tdap vaccinecompletedS
1953-10-20Influenza vaccine, 1953-1954 seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
31 March 1952Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecencyD (CLM-0003, CLM-0004)
1952Breast growth attributed to the hormone treatment, which he is known to have mentioned onceD (CLM-0005)
November 1952Decided to see a psychiatrist again and began Jungian analysisD (CLM-0006)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runnersactiveS
Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed toactiveS

Assessment

Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1953-10-20; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 1953-10-06; Total score [AUDIT-C] 2 on 1953-10-20; Testosterone [Mass/volume] in Serum or Plasma 536 on 1953-10-06; Estradiol (E2) [Mass/volume] in Serum or Plasma 24 on 1953-10-06; Lutropin [Units/volume] in Serum or Plasma 4.8 on 1953-08-04; Follitropin [Units/volume] in Serum or Plasma 5.2 on 1953-08-04; Sex hormone binding globulin [Moles/volume] in Serum or Plasma 88 on 1953-04-14; Prolactin [Mass/volume] in Serum or Plasma 12.4 on 1953-06-09; Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 on 1953-04-14; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 2.6 on 1953-04-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1953-04-14; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1953-04-14; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1953-04-14; Creatinine [Mass/volume] in Serum or Plasma 0.96 on 1953-04-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M 102 on 1953-04-14; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1953-04-14; Hemoglobin [Mass/volume] in Blood 14.4 on 1953-08-04; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 1953-10-06; Cholesterol [Mass/volume] in Serum or Plasma 182 on 1953-10-20; Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 on 1953-10-20; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 on 1953-10-20; Triglyceride [Mass/volume] in Serum or Plasma 80 on 1953-10-20 [S]

Strengths and supports: Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatmentactiveconfirmed N62S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic.
Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigueresolvedconfirmed E23.1S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops.
Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonmentactiveconfirmed T38.5X5AS — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm.
Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime)activeconfirmed F32.1S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R).
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)resolvedconfirmed E55.9S — Synthetic finding of the bone-health workup.
Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolvedresolvedconfirmed S93.401AS — Synthetic sprain at an unscheduled visit, chosen to teach the Ottawa ankle rules and how to protect a depression plan that relies on running; it does not echo any documented injury.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]15{score}S
1953-04-14Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1953-04-14Total score [AUDIT-C]2{score}S
1953-04-14Testosterone [Mass/volume] in Serum or Plasma112ng/dL264-916 ng/dLLowS
1953-04-14Estradiol (E2) [Mass/volume] in Serum or Plasma148pg/mL7.6-42.6 pg/mLHighS
1953-04-14Lutropin [Units/volume] in Serum or Plasma0.3m[IU]/mL1.7-8.6 m[IU]/mLLowS
1953-04-14Follitropin [Units/volume] in Serum or Plasma0.4m[IU]/mL1.5-12.4 m[IU]/mLLowS
1953-04-14Sex hormone binding globulin [Moles/volume] in Serum or Plasma88nmol/L16.5-55.9 nmol/LHighS
1953-04-14Prolactin [Mass/volume] in Serum or Plasma21.6ng/mL4-15.2 ng/mLHighS
1953-04-14Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma1m[IU]/mL<=3 m[IU]/mLNormalS
1953-04-14Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma2.6ng/mL<=8.3 ng/mLNormalS
1953-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
1953-04-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-48 U/LNormalS
1953-04-14Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1953-04-14Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.74-1.35 mg/dLNormalS
1953-04-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1953-04-14Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
1953-04-14Hemoglobin [Mass/volume] in Blood13g/dL13.2-16.6 g/dLLowS
1953-04-1425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma22ng/mL30-100 ng/mLLowS
1953-04-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]14{score}S
1953-04-28Estradiol (E2) [Mass/volume] in Serum or Plasma46pg/mL7.6-42.6 pg/mLHighS
1953-04-28Lutropin [Units/volume] in Serum or Plasma0.9m[IU]/mL1.7-8.6 m[IU]/mLLowS
1953-06-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S
1953-06-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1953-06-09Testosterone [Mass/volume] in Serum or Plasma238ng/dL264-916 ng/dLLowS
1953-06-09Estradiol (E2) [Mass/volume] in Serum or Plasma26pg/mL7.6-42.6 pg/mLNormalS
1953-06-09Lutropin [Units/volume] in Serum or Plasma2.4m[IU]/mL1.7-8.6 m[IU]/mLNormalS
1953-06-09Follitropin [Units/volume] in Serum or Plasma3.1m[IU]/mL1.5-12.4 m[IU]/mLNormalS
1953-06-09Prolactin [Mass/volume] in Serum or Plasma12.4ng/mL4-15.2 ng/mLNormalS
1953-06-09Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
1953-08-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1953-08-04Testosterone [Mass/volume] in Serum or Plasma452ng/dL264-916 ng/dLNormalS
1953-08-04Lutropin [Units/volume] in Serum or Plasma4.8m[IU]/mL1.7-8.6 m[IU]/mLNormalS
1953-08-04Follitropin [Units/volume] in Serum or Plasma5.2m[IU]/mL1.5-12.4 m[IU]/mLNormalS
1953-08-04Hemoglobin [Mass/volume] in Blood14.4g/dL13.2-16.6 g/dLNormalS
1953-10-06Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1953-10-06Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S
1953-10-06Testosterone [Mass/volume] in Serum or Plasma536ng/dL264-916 ng/dLNormalS
1953-10-06Estradiol (E2) [Mass/volume] in Serum or Plasma24pg/mL7.6-42.6 pg/mLNormalS
1953-10-0625-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mL30-100 ng/mLNormalS
1953-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1953-10-20Total score [AUDIT-C]2{score}S
1953-10-20Cholesterol [Mass/volume] in Serum or Plasma182mg/dL<=199 mg/dLNormalS
1953-10-20Cholesterol in HDL [Mass/volume] in Serum or Plasma62mg/dL>=40 mg/dLNormalS
1953-10-20Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation104mg/dL<=129 mg/dLNormalS
1953-10-20Triglyceride [Mass/volume] in Serum or Plasma80mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1953-04-14Body height178cmS
1953-04-14Body weight71.4kgS
1953-04-14Body mass index (BMI) [Ratio]22.5kg/m2S
1953-04-14Systolic blood pressure122mm[Hg]S
1953-04-14Diastolic blood pressure76mm[Hg]S
1953-04-14Heart rate64/minS
1953-04-14Respiratory rate14/minS
1953-04-14Body temperature36.6CelS
1953-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-04-28Body height178cmS
1953-04-28Body weight71kgS
1953-04-28Body mass index (BMI) [Ratio]22.4kg/m2S
1953-04-28Systolic blood pressure120mm[Hg]S
1953-04-28Diastolic blood pressure74mm[Hg]S
1953-04-28Heart rate62/minS
1953-04-28Respiratory rate14/minS
1953-04-28Body temperature36.5CelS
1953-04-28Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-06-09Body height178cmS
1953-06-09Body weight70.1kgS
1953-06-09Body mass index (BMI) [Ratio]22.1kg/m2S
1953-06-09Systolic blood pressure118mm[Hg]S
1953-06-09Diastolic blood pressure74mm[Hg]S
1953-06-09Heart rate58/minS
1953-06-09Respiratory rate14/minS
1953-06-09Body temperature36.6CelS
1953-06-09Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-08-04Body height178cmS
1953-08-04Body weight69.3kgS
1953-08-04Body mass index (BMI) [Ratio]21.9kg/m2S
1953-08-04Systolic blood pressure124mm[Hg]S
1953-08-04Diastolic blood pressure78mm[Hg]S
1953-08-04Heart rate60/minS
1953-08-04Respiratory rate14/minS
1953-08-04Body temperature36.7CelS
1953-08-04Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-10-06Body height178cmS
1953-10-06Body weight68.6kgS
1953-10-06Body mass index (BMI) [Ratio]21.7kg/m2S
1953-10-06Systolic blood pressure118mm[Hg]S
1953-10-06Diastolic blood pressure72mm[Hg]S
1953-10-06Heart rate54/minS
1953-10-06Respiratory rate14/minS
1953-10-06Body temperature36.6CelS
1953-10-06Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-08-25Body height178cmS
1953-08-25Body weight69kgS
1953-08-25Body mass index (BMI) [Ratio]21.8kg/m2S
1953-08-25Systolic blood pressure126mm[Hg]S
1953-08-25Diastolic blood pressure78mm[Hg]S
1953-08-25Heart rate70/minS
1953-08-25Respiratory rate14/minS
1953-08-25Body temperature36.7CelS
1953-08-25Oxygen saturation in Arterial blood by Pulse oximetry99%S
1953-10-20Body height178cmS
1953-10-20Body weight68.5kgS
1953-10-20Body mass index (BMI) [Ratio]21.6kg/m2S
1953-10-20Systolic blood pressure116mm[Hg]S
1953-10-20Diastolic blood pressure72mm[Hg]S
1953-10-20Heart rate54/minS
1953-10-20Respiratory rate14/minS
1953-10-20Body temperature36.6CelS
1953-10-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1953-04-14New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consentfinishedS
1953-04-28Two-week follow-up with endocrinology consultation and scrotal ultrasoundfinishedS
1953-06-09Eight-week review of hormone recovery and depression treatmentfinishedS
1953-08-04Sixteen-week review of hormone recovery and depression treatmentfinishedS
1953-10-06Six-month review of gynecomastia and depression in continuation treatmentfinishedS
1953-08-25Same-day sick visit for a right ankle sprainfinishedS
1953-10-20Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be givencompletedGL-APA-SM-2021, GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018S
Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocalcompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018S
Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgerycompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018S
Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles himcompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018S
Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurscompletedGL-EAA-GM-2019, GL-ES-HYPOGONAD-2018, GL-ES-OSTEO-MEN-2012S
Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weekscompletedGL-MDD-2022, GL-CMID-2026, GL-APA-SM-2021S
Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visitcompletedGL-SUICIDE-2024, GL-CMID-2026S
Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recoverscompletedGL-CDC-STI-2021, GL-USPSTF-PREP-2023, GL-APA-SM-2021S
Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicatedcompletedGL-APA-SM-2021S
Add bupropion XL 150 mg each morning, chosen by him after an informed discussion of options and side effects; nurse telephone check at two weeks; PHQ-9 and blood pressure at each visitcompletedGL-CMID-2026, GL-MDD-2022S

Goals

GoalTargetStatusOutcomeProvenance
Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy1953-08-04completedTestosterone 452 ng/dL with normal LH and FSH at sixteen weeksS
Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him1953-10-06activeTenderness gone by six months; small residual glandular tissue; watchful waiting to twelve monthsS
Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5)1953-10-06completedPHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six monthsS
Back to running about 40 km a week and changing at his club again1953-10-06completedRunning 40 km a week and back with the club by six monthsS

Functional Status

Mental Status

Structured synthetic safety assessment on 1953-04-14: current ideation absent, intent absent, plan absent. Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, and a two-week follow-up [S]